Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammati...

Full description

Bibliographic Details
Main Authors: Stepan Coufal, Miloslav Kverka, Jakub Kreisinger, Tomas Thon, Filip Rob, Martin Kolar, Zuzana Reiss, Dagmar Schierova, Klara Kostovcikova, Radka Roubalova, Lukas Bajer, Zuzana Jackova, Martin Mihula, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Format: Article
Language:English
Published: Hindawi Limited 2023-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2023/1535484

Internet

http://dx.doi.org/10.1155/2023/1535484

Similar Items